According to estimates from MedPAC, negotiated rebates for diabetic therapy were equal to or greater than 50% in 2023
Alternatives for Patients Seeking Weight-Loss Treatment If compounded GLP-1 medications become harder to obtain, clinicians say patients still have evidence-based treatment options available
PharmaTher announced on February 2, 2026 a strategic initiative to pursue Health Canada approval for generic semaglutide, targeting broad dose coverage from 0.25 mg to 2.4 mg
Your price won'tflat monthly pricing means no surprise costs as your provider optimizes your treatment
By joining our affiliate program, you can share your experience with friends, family, and followers, all while earning rewards for every new patient who joins through your unique referral link
In the gnomAD database 15 , the rs10305420 T allele is most common in the European (40%) and Middle Eastern (38%) ancestry groups, followed by the Admixed American (28%), South Asian (20%) and East Asian (16%) ancestry groups, and least common in the African (7%) ancestry group